ESMO 2019 Prostate Cancer

Viewing 1-20 of 63 articles

ESMO 2019: Invited Discussant: The CARD Trial - Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Systemic Treatment: The Role of Chemotherapy and Androgen Receptor Targeted Therapy

ESMO 2019: Invited Discussant - Phase 3 PROfound Study for Metastatic Castration-resistant Prostate Cancer (LBA12)

ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial

ESMO 2019: The CARD Trial, A Randomized, Open-Label Study of Cabazitaxel vs Abiraterone or Enzalutamide in mCRPC, Discussion

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Advances in Pelvic Nodal Radiotherapy

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Is there a Role for Radical Surgery?

ESMO 2019: Efficacy and Safety of Nivolumab in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer in CheckMate 9KD

ESMO 2019: CARD: Randomized, Open-Label Study of Cabazitaxel vs Abiraterone or Enzalutamide in mCRPC

ESMO 2019: Invited Discussant - PROfound: A Phase 3 Study of Olaparib versus Enzalutamide or Abiraterone for mCRPC with Homologous Recombination Repair Gene Alterations

ESMO 2019: PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations

ESMO 2019: “M1|RT Comparison” in STAMPEDE, Benefit of Prostate Radiotherapy for Patients with Lymph Node Only or Bone Metastasis and No Visceral Metastases

ESMO 2019: CARD: Randomized, Open-label Study of Cabazitaxel vs Abiraterone or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

ESMO 2019: PROfound: Phase 3 Study of Olaparib versus Enzalutamide or Abiraterone for mCRPC with Homologous Recombination Repair Gene Alterations

ESMO 2019: Invited Discussant (LBA51, LBA52, 848PD, 849PD and 855PD) – Immunotherapy in mCRPC, PSMA Radionuclide Therapy and an Update M0 STAMPEDE Data

ESMO 2019: Conclusions and Perspectives on Genomic Tumor Boards

ESMO 2019: Managing Incidental Germline Findings: Ethical and Practical Challenges

ESMO 2019: Health-Related Quality of Life in a Randomized Phase 3 trial of Enzalutamide with Standard First Line Therapy for mHSPC: ENZAMET, an ANZUP-led, International, Co-Operative Group Trial - A Medical Oncologist's Perspective

ESMO 2019: Patient-Reported Outcomes From TITAN in Patients with Metastatic Castration-Sensitive Prostate Cancer

ESMO 2019: Invited Discussant: Patient Reported Outcomes in Metastatic Hormone-Naïve Prostate Cancer and Who to Give Primary Radiotherapy To?

1
2
3
4